NanoPulse: A Scalable Micromixing Method for Robust and Reproducible RNA-LNP Formulation Across All Scales

Claire Counil – Nanoparticle Formulation Scientist, Inside Therapeutics, Bordeaux, France; Milad Baroud – Postdoctoral Researcher, ART ARNm Inserm UMS 55 and LI2RSO – University of Orléans, Orléans, France; Matthieu Kerhuel – Chief Technology Officer, Inside Therapeutics, Bordeaux, France; Robin Oliveres – Chief Business Officer, Inside Therapeutics, Bordeaux, France; Thomas Guérinier – Chief Executive Officer, Inside Therapeutics, Bordeaux, France; Chantal Pichon – Professor, ART ARNm Inserm UMS 55 and LI2RSO – University of Orléans, Orléans, France; Marie Bonnin – Associate Professor, SFR ICAT, Angers, MINT, Univ Angers, Inserm, CNRS, France; Brice Calvignac – Professor, SFR ICAT, Angers, MINT, Univ Angers, Inserm, CNRS, France; Audrey Nsamela – Chief Scientific Officer, Inside Therapeutics, Bordeaux, France

Introduction:

Lipid nanoparticles (LNPs) are the leading non-viral vector for RNA vaccines and therapeutics, but current workflows remain poorly scalable. Microfluidic methods offer excellent control at discovery scale yet lack throughput, while macroscale approaches such as T-mixing or impingement jet mixing introduce material loss and inconsistent critical quality attributes (CQAs) during scale-up, impacting biological performance [1,2]. We introduce NanoPulse (Figure 1), a patented micromixing platform enabling volume-independent RNA-LNP formulation, yielding nanoparticles with consistent physicochemical properties and robust biological performance.